QUOTE AND NEWS
Benzinga  May 10  Comment 
Pain Therapeutics Inc. (NASDAQ: PTIE) dipped 47.74% to $2.78 after the company CEO revealed a letter from Pfizer (NYSE: PFE) of reassessing its endorsement of the Remoxy program. DURECT Corporation (NASDAQ: DRRX) fell 41.50% to 0.93 after...
StreetInsider.com  May 10  Comment 
Pain Therapeutics (NASDAQ: PTIE) 48% LOWER; fizer said they saw a regulatory path forward for Remoxy but given new guidance, there will likely be a significant delay before they submit a Complete Response letter to the FDA guidance, likely in...
Benzinga  May 10  Comment 
Pain Therapeutics Inc. (NASDAQ: PTIE) dipped 45.01% to $5.32 in the pre-market session after the company CEO revealed a letter from Pfizer (NYSE: PFE) of reassessing its endorsement of the Remoxy program. Santarus, Inc. (NASDAQ: SNTS) shares...
StreetInsider.com  Apr 24  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Pain+Therapeutics+Inc.+%28PTIE%29+Reports+In-Line+Q1+Loss+of+1cShare/8274314.html for the full story.
StreetInsider.com  Feb 6  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Pain+Therapeutics+Inc.+%28PTIE%29+Posts+Q4+Loss+of+8cShare/8064189.html for the full story.
Benzinga  Dec 8  Comment 
Pain Therapeutics (NASDAQ: PTIE) announced today that a committee of its Board of Directors has declared a special one-time cash distribution of $0.75 per share to shareholders, or an aggregate of about $34 million. The Record Date for this...
Benzinga  Aug 17  Comment 
CK Cooper & Company initiated its coverage on Pain Therapeutics (NASDAQ: PTIE) with a Buy rating and a price target of $12. CK Cooper & Company commented, "Rather than risk the chance that we miss time an impending update on Remoxy, we are...
StreetInsider.com  Aug 2  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Pain+Therapeutics+Inc.+%28PTIE%29+Posts+Break+Even+Q2+Loss%3B+Revs+Light/7625568.html for the full story.





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki